Heart Failure Clinical Trial
— MEVADEOfficial title:
Medical Care Versus Ventricular Assist Device in Patients With NYHA Class IV Congestive Heart Failure: a Non Randomized Comparison of Clinical and Economic Outcomes
Verified date | April 2017 |
Source | Groupe Hospitalier Pitie-Salpetriere |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
End-stage heart failure (ESHF) represents a major burden in terms of quality of life, mortality and costs. The current practice in France is to treat patients with ESHF by a combination of drugs and lifestyle interventions before proposing heart transplant (HT) if there is no contraindication. In the Heart and Diabetes Center of Bad Oyenhausen (BO) in Germany, patients presenting with ESHF are preferentially managed by ventricular assist device (VAD) therapy. The primary purpose of this study was to compare the outcomes of these two strategies in the management of ESHF and associated consumption of resources.
Status | Completed |
Enrollment | 224 |
Est. completion date | January 2014 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 76 Years |
Eligibility |
Inclusion Criteria: All patients presenting with end-stage heart failure defined as: - A left ventricular ejection fraction =25% - Or an oxygen consumption peak < 14 mL/kg/min - Or severe symptoms (NYHA class III or IV) despite optimal medical treatment - Or a cardiogenic shock Exclusion Criteria: - Age over 70 years - Active neoplasia - Suspected or active systemic infection - Body mass index =40 kg/m2 - Severe chronic obstruction pulmonary disease - Evidence of intrinsic hepatic diseases defined as liver enzyme values = 5 times the upper limit of normal within 4 days before the randomisation, or biopsy proven liver cirrhosis - Significant chronic renal impairment with persistent creatinine >2.5 or clearance < 25ml/min - Pregnant or lactating female - Patient under consideration for conventional revascularization procedures, therapeutic valvular repair, left ventricular procedure or cardiomyoplasty - Presence of implanted mechanical aortic valve that will not be converted to bioprothesis at the time of ventricular assist device implantation - Evidence of intrinsic hepatic diseases defined as liver enzyme values = 5 times the upper limit of normal, or biopsy proven liver cirrhosis - Occurrence of stroke within 90 days or history of cerebrovascular disease with major (= 80%) extracranial or carotid stenosis documented by Doppler study - Confirmation by neurologist of impairment of cognitive function, presence of Alzheimer's disease or any other form of irreversible dementia or both - Major peripheral vascular disease accompanied by pain on rest or leg ulceration - Recent history of psychiatric disease that is likely to impair compliance - Drug or alcohol dependence - Difficult social surroundings |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Joe Elie Salem |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | The primary outcome was comparison of survival at two years between the two treatment strategies | two years | |
Secondary | Resource consumption | One secondary outcomes was comparison of the treatment strategies up to two years of follow-up about resource consumption. | Two years | |
Secondary | Costs | One secondary outcomes was comparison of the treatment strategies up to two years of follow-up about costs. | Two years | |
Secondary | Costs versus survival | One secondary outcomes was comparison of the treatment strategies up to two years of follow-up about costs versus survival. | Two years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|